Viatris 

$16.32
1588
-$0.16-0.97% Monday 20:00

Statistics

Day High
16.62
Day Low
16.29
52W High
17.53
52W Low
8.63
Volume
10,845,075
Avg. Volume
-
Mkt Cap
18.79B
P/E Ratio
-
Dividend Yield
2.94%
Dividend
0.48

Upcoming

Dividends

2.94%Dividend Yield
Jun 26
$0.12
Mar 26
$0.12
Dec 25
$0.12
Sep 25
$0.12
Jun 25
$0.12
10Y Growth
N/A
5Y Growth
7.78%
3Y Growth
N/A
1Y Growth
N/A

Earnings

10AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
0.49
0.58
0.66
0.75
Expected EPS
0.606396
Actual EPS
N/A

Financials

-24.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
28.6BRevenue
-7.03BNet Income

Analyst Ratings

18.75Average Price Target
The highest estimate is 22.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VTRS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Show more...
CEO
Mr. Scott Andrew Smith Ph.D.
Employees
32000
Country
United States
ISIN
US92556V1061

Listings

0 Comments

Share your thoughts

FAQ

What is Viatris stock price today?
The current price of VTRS is $16.32 USD — it has decreased by -0.97% in the past 24 hours. Watch Viatris stock price performance more closely on the chart.
What is Viatris stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Viatris stocks are traded under the ticker VTRS.
Is Viatris stock price growing?
VTRS stock has risen by +0.74% compared to the previous week, the month change is a -0.97% fall, over the last year Viatris has showed a +81.54% increase.
What is Viatris market cap?
Today Viatris has the market capitalization of 18.79B
When is the next Viatris earnings date?
Viatris is going to release the next earnings report on August 10, 2026.
What were Viatris earnings last quarter?
VTRS earnings for the last quarter are 0.59 USD per share, whereas the estimation was 0.5 USD resulting in a +17.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Viatris revenue for the last year?
Viatris revenue for the last year amounts to 28.6B USD.
What is Viatris net income for the last year?
VTRS net income for the last year is -7.03B USD.
Does Viatris pay dividends?
Yes, VTRS dividends are paid quarterly. The last dividend per share was 0.12 USD. As of today, Dividend Yield (FWD)% is 2.94%.
How many employees does Viatris have?
As of June 16, 2026, the company has 32,000 employees.
In which sector is Viatris located?
Viatris operates in the Health & Wellness sector.
When did Viatris complete a stock split?
Viatris has not had any recent stock splits.
Where is Viatris headquartered?
Viatris is headquartered in Canonsburg, United States.